Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

α-synuclein

Method of Measurement (Pre-analytical Tools)
CSF
Biomarker Measured
Amyloid
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Completed
Aim/Results

Levels of α-synuclein in the CSF were marginally higher in people with Alzheimer’s disease compared with controls (effect size = 1.169, p = 0.00853).

What is Required from Patients

Invasive lumbar puncture, discomfort, recovery time in clinic to decrease risk of spinal fluid leakage

What is Required from the Health System

physician who can preform a lumbar puncture as well as a clinic designed for this testing, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

Data collected by multiple groups. Alzforum meta analysis.

  1. “Alzheimer's Disease vs Control: α-synuclein (CSF).” Alzbiomarker. https://www.alzforum.org/alzbiomarker/meta-analysis/alzheimers-disease-vs-control-synuclein-csf

  2. Korff, A., Liu, C., Ginghina, C., Shi, M., Zhang, J., & Alzheimer's Disease Neuroimaging Initiative. (2013). α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. Journal of Alzheimer's Disease, 36(4), 679-688. https://www.ncbi.nlm.nih.gov/pubmed/23603399

  3. Öhrfelt, A., Grognet, P., Andreasen, N., Wallin, A., Vanmechelen, E., Blennow, K., & Zetterberg, H. (2009). Cerebrospinal fluid α-synuclein in neurodegenerative disorders—a marker of synapse loss? Neuroscience letters, 450(3), 332-335. https://www.ncbi.nlm.nih.gov/pubmed/19022350

  4. Twohig, D., Rodriguez-Vieitez, E., Sando, S. B., Berge, G., Lauridsen, C., Møller, I., ... & Benzinger, T. L. (2018). The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease. Acta neuropathologica communications, 6(1), 130. https://www.ncbi.nlm.nih.gov/pubmed/30477568